Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
Contraception ; 69(3): 247-50, 2004 Mar.
Article En | MEDLINE | ID: mdl-14969674

This study investigated the acceptability of the levonorgestrel-releasing intrauterine device (LNG-IUS) as contraception among young, single women after termination of pregnancy. Twenty subjects, with a median age of 21 years, had LNG-IUS inserted immediately after suction termination of first-trimester pregnancy. The subjects were followed-up at 6 weeks, 3 months, 6 months and 12 months. Fifteen subjects (75%) had other pregnancies terminated in the past. There were no serious complications or pregnancies. The acceptability of the LNG-IUS was generally above 86% during each follow-up visit. A total of seven (35%) subjects were lost to follow-up at different periods of the study. Overall, four subjects (22%) had the LNG-IUS removed. Nine subjects were seen at the end of the 1-year study period and all continued with the LNG-IUS for contraception. Side effects were commonly observed and irregular vaginal bleeding was the most common. We conclude that the LNG-IUS may be an acceptable method among selective young, single, nulliparous clients after termination of pregnancy and could be offered as an option of contraception to them. However, the small sample size and the high lost-to-follow-up rate are the major limitations of this study.


Contraceptive Agents, Female/administration & dosage , Intrauterine Devices, Medicated/statistics & numerical data , Levonorgestrel/administration & dosage , Patient Acceptance of Health Care/statistics & numerical data , Abortion, Induced , Adolescent , Adult , China , Contraceptive Agents, Female/adverse effects , Female , Follow-Up Studies , Humans , Intraoperative Period , Intrauterine Devices, Medicated/adverse effects , Levonorgestrel/adverse effects , Pilot Projects , Prospective Studies
2.
Contraception ; 68(4): 269-72, 2003 Oct.
Article En | MEDLINE | ID: mdl-14572890

This was a double-blind randomized control study to evaluate the efficacy of cervical priming by nitric oxide donor before second-trimester induced abortion. One-hundred healthy women with a singleton pregnancy between 14 and 20 weeks of gestation were randomized into either 40 mg isosorbide mononitrate or placebo, given intravaginally 12 h before induction. This was followed by intravaginal misoprostol induction. The induction-abortion interval, abortion rate, side effects and the woman's acceptability of the priming agent were recorded. All women completed the study and there was no severe complication recorded. There was no significant difference in the induction-abortion interval and abortion rate between the two groups. Isosorbide mononitrate group reported significantly more side effects of headache. More than 90% of the women in both groups found the priming agent acceptable. The application of intravaginal nitric oxide donors prior to the prostaglandins induction did not significantly improve the second-trimester induced-abortion process.


Abortion, Induced/methods , Cervical Ripening , Isosorbide Dinitrate/analogs & derivatives , Isosorbide Dinitrate/administration & dosage , Nitric Oxide Donors/administration & dosage , Abortifacient Agents, Steroidal/administration & dosage , Administration, Intravaginal , Adult , Double-Blind Method , Female , Humans , Isosorbide Dinitrate/adverse effects , Misoprostol/administration & dosage , Nitric Oxide Donors/adverse effects , Pregnancy , Pregnancy Trimester, Second , Prospective Studies , Treatment Outcome
3.
Contraception ; 67(2): 101-5, 2003 Feb.
Article En | MEDLINE | ID: mdl-12586320

This double-blind randomized control study was conducted to evaluate whether a nonsteroidal anti-inflammatory drug (NSAID) could act as an effective pain control method during first trimester suction abortion, and whether co-treatment of NSAID with misoprostol will decrease the efficacy of the cervical ripening effect of misoprostol. Subjects were randomized to receive misoprostol alone or misoprostol together with diclofenac sodium. Both groups of subjects suffered from similar incidence of preoperative side effects. Co-treatment of NSAID with misoprostol did not attenuate the cervical ripening efficacy of misoprostol. There was no significant pain reduction in the group treated with NSAID, except that a marginal benefit was found in the subgroup of multiparous women. About two thirds of the subjects in both treatment groups found that this was a satisfactory pain relief method during the procedure.


Abortifacient Agents, Nonsteroidal/administration & dosage , Abortion, Induced/methods , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cervix Uteri/physiology , Misoprostol/administration & dosage , Abortifacient Agents, Nonsteroidal/adverse effects , Adolescent , Adult , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Cervix Uteri/drug effects , Diclofenac/administration & dosage , Diclofenac/adverse effects , Double-Blind Method , Drug Interactions , Female , Humans , Misoprostol/adverse effects , Pain , Pregnancy , Pregnancy Trimester, First , Premedication , Prospective Studies , Suction
...